Prolonged oral versus high-dose intravenous etoposide in combination with carboplatin for stage IV non-small-cell lung cancer (NSCLC): A randomized trial

Lung Cancer

Volumn 25, Issue 3, 1999, Pages 207-214

  Jeremic, Branislav ^a   Shibamoto, Yuta ^b   Milicic, Biljana ^a   Milisavljevic, Slobodan ^a   Nikolic, Nebojsa ^a   Dagovic, Aleksandar ^a   Aleksandrovic, Jasna ^a   Radosavljevic Asic, Gordana ^c  

^a University Hospital   (Serbia)

^b KYOTO UNIVERSITY   (Japan)

^c Clinical Center   (Serbia)

Author keywords

Carboplatin; Etoposide; Metastatic disease; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; FEVER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 0032874479     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00061-6     Document Type: Article

References (48)

1. Ihde D.C. Chemotherapy of lung cancer. New Engl J Med. 327:1992;1434-1441.
2. Johnson D.H. Chemotherapy for unresectable non-small cell lung cancer. Semin Oncol. 17(Suppl 7):1990;20-29.
3. Finkelstein D.M., Ettinger D.S., Ruckdeschel J.C. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 4:1986;702-709.
4. Albain K.S., Crowley J.J., Leblanc M., Livingston R.B. Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 9:1991;1618-1626.
5. Dombernowsky P., Nissen N.I. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP-16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microb Scand (A). 81:1973;715-724.
6. Clark P.I., Slevin M.L. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet. 12:1987;223-252.
7. Pedersen A.G., Hansen H.H. Etoposide (VP-16) in the treatment of lung cancer. Cancer Treat Rev. 10:1983;245-264.
8. Bonomi P. Recent advances in etoposide therapy for non-small cell lung cancer. Cancer. 67(Suppl 1):1991;254-259.
9. Fleming R.A., Miller A.A., Stewart C.F. Etoposide: an update. Clin Pharm. 8:1989;274-293.
10. Ruckdeschel J.C. Etoposide in the management of non-small cell lung cancer. Cancer. 67(Suppl 1):1991;250-253.
11. Hainsworth J.D., Johnson D.H., Frazier S.R., Greco F.A. Chronic daily administration of oral etoposide: a phase I trial. J Clin Oncol. 7:1989;396-401.
12. Bonomi P., Finkelstein D.M., Ruckdeschel J.C. et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 7:1989;1602-1613.
13. Jeremic B., Acimovic L., Matovic M. Carboplatin and etoposide in patients with advanced gastric cancer. J Chemother. 5:1993;266-270.
14. Jeremic B., Acimovic L., Mijatovic L. Carboplatin and etoposide in advanced colorectal carcinoma. A phase II study. Cancer. 71:1993;2706-2708.
15. Jeremic B., Grujicic D., Jevremovic S., Stanisavljevic B., Milojevic L., Mijatovic L. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma. A phase II study. J Clin Oncol. 10:1992;1074-1077.
16. Klastersky J., Sculier J.P., Lacroix H. et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol. 8:1990;1556-1562.
17. Lyss A., Perry M., Propert K., Green M. Etoposide (VP 16)/Carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC): a phase II study. Proc Am Soc Clin Oncol. 7:1988;206. (Abstract 795).
18. Lyss A.P., Perry M.C., Propert K., Goutsou M., Green M. VP16/Carboplatin (CBDCA) therapy in advanced non-small cell lung cancer: a phase II study. Proc Am Soc Clin Oncol. 8:1989;232. (Abstract 903).
19. Souquet P.J., Chauvin F., Boissel J.P. et al. Polychemotherapy in advanced non-small cell lung cancer: a meta analysis. Lancet. 342:1993;19-21.
20. Grilli R., Oxman A.D., Julian J.A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol. 11:1993;1866-1872.
21. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J. 311:1995;899-909.
22. Marino P., Preatoni A., Cantoni G., Buccheri G. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer. 13:1995;1-12.
23. Lilenbaum R.C., Langenberg P., Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung cancer. A meta-analysis of response, toxicity, and survival. Cancer. 82:1998;116-126.
24. Abratt R.P., Bezwoda W.R., Goedhals L., Hacking D.J. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 15:1997;744-749.
25. Bonomi P., Kim K., Chang A., Johnson D. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol. 15:1996;382. (Abstract 1145).
26. Depierre A., Chastang C., Quoix E. et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small-cell lung cancer: a randomized trial. Ann Oncol. 5:1994;37-42.
27. Giaccone G., Splinter T., Postmus P. et al. Paclitaxel-cisplatin versus teniposide-cisplatin in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 15:1996;373. (Abstract 1109).
28. Hainsworth J.D., Thompson D.S., Urba W.J. et al. One hour paclitaxel plus carboplatin in advanced non-small cell lung cancer (NSCLC): preliminary results of a multi-institutional phase II study. Proc Am Soc Clin Oncol. 15:1996;379. (Abstract 1131).
29. Johnson D.H., Paul D.M., Hande K.R. et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol. 14:1996;2054-2060.
30. Langer C.J., Leighton J.C., Comis R.L. et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): a phase II toxicity, response, and survival analysis (FCCC 93-024). J Clin Oncol. 13:1995;1860-1870.
31. LeChevalier T., Brisgand D., Douillard J.-Y. et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 12:1994;360-367.
32. Jeremic B., Shibamoto Y., Acimovic L., Milicic B., Milisavljevic S., Nikolic N. Prolonged administration of oral etoposide alone or with intravenous carboplatin in stage IV non-small cell lung cancer: a randomized trial. Lung Cancer. 18:1997;179-188.
33. Johnson D.H., Hainsworth J.D., DeVore R., Hande K.R., Greco F.A. Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt Trial. Oncology. 49(Suppl 1):1992;57-62.
34. Hirabayashi M., Tanaka Y., Hitoshi Y., Nakagawa M., Kuno K. Treatment of unresectable non-small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide. Jpn J Cancer Chemother. 21:1994;53-58.
35. Frasci G., Perrilo G., Comella G. et al. Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced non-small cell lung cancer. Cancer. 75:1995;1578-1585.
36. Frasci G., Comella P., Del Gazio F. et al. Carboplatin (CBDCA) - oral etoposide (VP 16) personalized dosing in elderly or poor performance status NSCLC patients. Lung Cancer. 18(Suppl 1):1997;38. (Abstract 141).
37. 2 in patients with advanced non small cell lung cancer (NSCLC): is there an impact of the reached area under the curve (AUC) on response, survival, and hematological toxicity? Lung Cancer. 18(Suppl 1):1997;43. (Abstract 161).
38. Lyss A.P., Perry M.C., Goutsou M. et al. Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A phase II trial of the Cancer and Leukemia Group B. Am J Clin Oncol (CCT). 15:1992;399-404.
39. Helsing M., Bergman B. Chemotherapy with carboplatin and etoposide improves quality of life and survival in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 18(Suppl 1):1997;8. (Abstract 22).
40. Furuse K. Platinum/oral etoposide therapy in non-small cell lung cancer. Oncology. 49(Suppl 1):1992;63-69.
41. Estape J., Palombo H., Sanchez-Lloret J. et al. Chronic oral etoposide in non-small cell lung carcinoma. Eur J Cancer. 28A:1992;835-837.
42. Kakolyris S., Samonis G., Koukourakis M. et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol (CCT). 21:1998;505-508.
43. Miller A.A., Tolley E.A., Niell H.B., Griffin J.P., Mauer A.M. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol. 11:1993;1179-1188.
44. Robert F., Wheeler R.H., Molthrop D., Bailey A., Chen S. Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer. Am J Clin Oncol (CCT). 17:1994;383-386.
45. Warner E., Goel R., Chang J. et al. A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). Br J Cancer. 77:1998;2376-2380.
46. Blumenreich M.S., Sheth S.P., Miller C.L. et al. Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer. Am J Clin Oncol (CCT). 17:1994;163-165.
47. Saxman S., Loehrer P.J. Sr., Logie K. et al. Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer. Invest New Drugs. 9:1991;253-256.
48. Klastersky J., Sculier J.P., Bureau G. et al. Cisplatin versus cisplatin pluis etoposide in the treatment of advanced non-small-cell lung cancer, Lung Cancer Working Party, Belgium. J Clin Oncol. 7:1989;1087-1092.